Immunotherapy reaches Breakthrough in eliminating HIV
Immunocore has published key results for its new preclinical candidate for HIV, ImmTAV. This TCR-based…
Immunocore has published key results for its new preclinical candidate for HIV, ImmTAV. This TCR-based…
CRISPR remains in the spotlight as the scientific discovery of the century. A long list…
This is the story of a French doctor and his start-ups which have been trying to develop…
The US Giant Gilead is opening a new program of Grants to fund the next generation…
MD Anderson (US) and the Berlin Biotech Mologen (Germany) have now partnered on for an Immuno-Oncology program fighting…
Abivax in Paris (France) has released its phase IIa clinical results for an antiviral therapy…
"The RNA People" at CureVac in Tübingen (Germany) have a new €100M investment into their…
One more hit to Moderna Therapeutics struck by its German competitor CureVac! The Tübingen-based company just announced the opening…
HIV is definitely under the spotlight today. Just after Theravectys' announcement about its phase I/II success, InnaVirVax completed a…
Theravectys just announced positive results of its HIV drug candidate in a phase I/II study. The therapeutic…
Abivax has ended the paperwork and launched its IPO on Euronext Paris, where the biotech…
THERAVECTYS, a fully-integrated discovery and clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapy,…